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ABSTRACT 
 
 
Flavonoids are a long and well known class of natural products. Their potential health 
benefits can be attributed to their antioxidant activity, and modulation of cell signaling 
pathways. Green tea one of the most widely consumed beverages, consist of flavonoids 
such as catechins and tannins. Epigallocatechin gallate (EGCG) the major catechin of 
green tea exhibits multiple health benefits due to its antioxidant nature. The radical 
scavenging activity of EGCG is attributed to its structure. Therefore, a study on 
molecular features of EGCG would provide valuable information on structural 
modifications, which may change the physiochemical properties such as bioavailability 
and solubility.                
     Although flavonoids are abundant and commercially available they are difficult to 
purify and crystallize. In this respect, crystallizing EGCG was challenging. By exploring 
different techniques EGCG was crystallized. Here in this study one new form of EGCG 
and two solvates, acetonitrile and nitrobenzene, have been synthesized and structurally 
characterized by differential scanning calorimetry (DSC), infrared (IR) and powder X-ray 
diffraction (PXRD).  The crystal structures were solved by single-crystal X-ray 
diffraction and a detailed description of synthesis and about the supramolecular synthons 
that exist in these crystal forms are given. 
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1. INTRODUCTION 
 
1.1   Flavonoids 
1.1.1 History                                                                                                                          
Flavonoid compounds, which are ubiquitous in nature, occupy a prominent position 
among the plant phenols. Though flavonoids are present in other parts of plants, many 
flavonoids are easily recognized as flower pigments in most angiospermic plants. 3 
Flavonoids are distributed in higher plants, bacteria, algae, fungi, and animals. The 
earliest suggestion that substances existed in nature that would eventually be recognized 
as flavonoids can be traced back to the 17th century.  In 1682 Nehemiah Grew discussed 
the differences between the solubility properties of pigments, which can be recognized as 
the starting point for naturally occurring compounds. 1 Flavonoids are responsible for 
coloration of the plants. Autumn coloration of leaves has attracted the attention of many 
workers for years. Anthocyanin pigments have played a major role in the history of 
naturally occurring compounds. 
     The term “flavone” first appeared in a paper by Kostanecki and Tambor (1895). 1 In 
1893 De Larie and Tiemann obtained the first isoflavone from the rhizomes of “Iris 
Florentina”.  The first flavanone recognized as naturally occurring was butrin 1 and the 
first isoflavanoid discovered structurally is “Prunetin” described by Finnamore (1910). 1  
 
 
St.Von Kostanecki first established the basic structure of the flavones and synthesized a 
number of natural compounds. 2 In a continuation to these studies, Herzig and A.G Perkin 
determined the positions of attachment of sugar residues in the glycosides. 2   Out of all 
the flavonoids, anthocyanins are the first compounds which were studied in detail. This is 
due to their wide abundance in nature as a coloring compound in plants. 
1.1.2 Structure 
     Flavonoids are based on a 15 carbon atom skeleton. A simple way to describe the 
flavonoid skeleton is, two phenyl rings connected by three carbon-bridges. It can also be 
represented as C6 – C3 – C6.  
                          
                                            Figure 1.1: Skeleton of Flavonoid 
 
      The chemical structure of the flavonoids are based on a C15 skeleton with a chromane 
ring bearing a second aromatic ring B in position 2,3 or 4. 3
             
                        
                                       Figure 1.2: Structural representation of Flavonoids 
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     In certain flavonoids the C ring is either in an open form or replaced by a five 
membered ring (eg: aurones). 
1.1.3 Classification of Flavonoids 
                                 
                                                                                                                             
                     Figure 1.3: Chalcone                                              Figure 1.4: Skeleton of Flavone 
 
 
                
         Figure 1.5: Quericetol                                                 Figure 1.6: Skeleton of Flavanone 
 
                      
               Figure 1.7: Anthocyanins                                              Figure 1.8: Skeleton of Isoflavonoid 
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                                            Figure 1.9: Skeleton of Neoflavonoids 
 
     Flavonoids are classified according to the substitution pattern of the C-ring. The 
oxidation state of the heterocyclic ring and the position of the B ring are also considered 
in classifying flavonoids. There are 6 major sub groups of flavonoids. 3
      Chalcones, (Fig: 1.3) the first sub class of flavonoids contain three carbons – bridge 
in open form. 5 Flavones (Fig: 1.4) are based on the backbone of 2-phenylchromen-4-one 
(2-phenyl-1-benzopyran-4-one). Generally, found in herbaceous families like Labiatae, 
Umbellifereae, and Compositae etc. 3, 4 Flavanols (Fig: 1.5) contain a hydroxyl group at 
C-3 position (Eg: Quericetol). In flavanone (Fig: 1.5) the hydroxyl group at C-3 position 
is absent. Anthocyanins (Fig: 1.6) are considered as major class of pigments. Isoflavanoid 
(Fig: 1.7) are isomeric to flavones by virtue of their having the B-ring attached to 
position-3 rather than position-2 as in flavones. 1, 3 Neoflavonoids (Fig1.8) contain B-ring 
in 4th position. Derived from the 4-phenylcoumarine (4-phenyl-1, 2-benzopyrone) 
structure. 3, 6 
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1.1.4 Occurrence and distribution of Flavonoids 
        Although flavonoids are widely distributed in nature and in foods, they lack uniform 
distribution throughout the plant kingdom. Flavonoid compounds occur in all parts of the 
higher plants: roots, stems, leaves, flowers, pollen, fruit, seeds, wood and bark. Ferns 
contain many flavonoid compounds of the types found in flowering plants. 2 Different 
food items contain varying concentrations of flavonoids. Teas, fruits, and dark chocolates 
contain moderate to high concentrations of flavonoids.  Vegetables like broccoli and 
some fruit juices like cranberry and orange provide low levels of flavonoid content. Black 
and oolong tea contents have high contents of derived tannins. 7
1.1.5 Extraction and Purification 
       Different parameters effect the extraction of the flavonoids from plant materials; 
their chemical nature, storage time and conditions, and the presence of interfering 
substances. The solubility of the flavonoids depend upon the polarity of the solvent used, 
degree of polymerization, interaction with other food constituents and formation of 
insoluble complexes. There is no uniform or completely satisfactory procedure that is 
suitable for extraction of all flavonoids or specific type of flavonoids in plant materials. 
The most commonly used solvents in extraction of these compounds are methanol, ethyl 
acetate, acetone, and water, their combinations are also used.  Propanol and 
dimethylformamide, are also used but to a lesser extent. Extraction period usually varies 
from 1min to 24 hrs. 
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 Extraction of polyphenols from food constituents also depends on sample-solvent ratio.  
       The Flavonoid extracts can be partially purified, using ion exchange resins. Extracts 
can also be purified and fractioned by using solid phase extraction or solid phase 
microextraction (SPME), and column chromatography. Different columns are used for 
extraction of flavonoids, like C-18 column, Sephadex column etc.  Recently counter 
current chromatography (CCC) has been used as an alternative to liquid chromatography 
for fractionation of various flavonoids.  High speed centrifugal countercurrent 
chromatography is used in the separation of flavonoids like tea catechins, anthocyanins, 
theaflavins, etc. 8  
     Quantification of flavonoids is carried out by different spectroscopic techniques. Gas 
Chromatography (GC) and high performance liquid chromatography (HPLC) are widely 
used in separation and quantitation of flavonoids. Structure elucidation is carried out by a 
combination of GC or HPLC with mass spectrometry and also various other relevant 
techniques. 8
1.1.6 Uses 
       Due to their beneficial health effects, flavonoids have garnered more interest in the 
past 2 decades. It was initially hypothesized that pharmacological effects of flavonoids 
would be related to their antioxidant activity, but the available evidence from cell culture 
experiments suggested that modulation of cell signaling pathway by flavonoids was 
attributed to their most of the biological effects. Studies in cell cultures have suggested 
that flavonoids may affect the chronic disease by inhibiting the kinases. 115  
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 Flavonoids have a wide range of beneficial health effects such as, reducing the risk of 
cancer, 116,117 anti-inflammatory, 118 reducing the risk of developing diabetes mellitus, 119 
infertility, 120 anticholesterolemia, 121 antiatherosclerosis, 121 antiulcer, ability to inhibit 
human platelet aggregation, 123 reducing the skin wrinkling, and also in reducing the risk 
of cardiovascular diseases. 124 Flavonoids are most widely used as dietary supplements. 
 
1.2 Green Tea 
1.2.1 History 
       Green tea one of the most widely consumed beverages in the world is an aqueous 
infusion of dried leaves of “Camellia Sinensis”. The birth place of green tea is in Asia. 
Tea plants grow only in warm climates. Although abundant foilage is produced by the tea 
plant, only the two leaves and the buds at each young shoot are picked for tea. The type 
of tea produced depends on the way in which leaves are processed: green, oolong, black. 
Green tea is the least processed tea; it is made by steaming the harvested leaves, rolling 
them and then spreading them out to dry until they become crispy (14).    
        The chemical contents of green tea include; flavonoids such as catechins and 
tannins, free amino acids, caffeine, ascorbic acid, saponins, and unsaturated fatty acids. 15, 
16 Catechins constitute a major component of green tea, which include Epicatechin (EC), 
Epigallocatechin (EGC), Epicatechin gallate (ECG), Epigallocatechin gallate (EGCG). 
These compounds constitute 30% of the chemical composition of green tea. 12, 13 The 
most active component of green tea is EGCG, which constitutes 9-13% weight of green 
tea. It possesses a much greater antioxidant activity than the other catechins, and plays an  
 
important role in the prevention of cancer and cardiovascular diseases. 17
             A literature Search through Scifinder reveals that there are more than 8000 
citations related to chemistry, bioactivity, production and potential health benefits of  
green tea. Out of 8000, 4000 references are related to EGCG and other natural products 
of green tea. 18
 
 
 
 
 
 
 
 
 
                                               Figure 1.10 : Structure of EGCG 
 
1.2.2 Green tea production and trade 
     World wide annual production of tea is estimated around 1 million tonnes and 70 
percent of it is black tea and remaining is green tea. The world’s major producers of 
green tea are China, Japan, Korea, Taiwan, and Indonesia. China accounts for 65 percent 
of world production and 85 percents of world exports of green tea, where as Japan 
accounts for 20 percent of world production and five percent of world exports. United 
States of America and Canada are the major export destinations of green tea. It is also 
exported to Germany, United Kingdom, and Saudi Arabia. 11
 8
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1.2.3 Extraction and purification of green tea.  
     Various methods are used in extracting and purifying green tea. Most of these  
methods are patented. As EGCG is the principal active ingredient of green tea, most of  
the methods in extracting green tea are concentrated on extracting the pure EGCG. In 
most of the methods, polyphenols of green tea are extracted by solvent extraction, using 
different solvents like water, ethanol, diethyl ether, ethyl acetate, acetone etc.  
Purification of green tea is performed by using chromatographic techniques. Different 
types of columns are used in the separation of polyphenols, like Sephadex LH 20 column, 
19 Silica gel column, 20 C-18 attached silica monolith microcolumns, 24 and 
Lignocellulose column. 25 Different lengths and particle size of HPLC columns are used 
for separation of catechins. 21 Weakly basic anion exchange resins are also used in the 
separation of polyphenols. 22 Polyphenols of green tea are also separated by Reverse 
phase liquid chromatography, and High speed counter current chromatography. 26, 27 
During the purification process the time and temperature at which brewing is performed, 
is also considered (higher the brewing time higher the concentration of the catechins in 
green tea). 70◦C is recognized as the optimum temperature for achieving the maximum 
concentration of polyphenols. 23  
       EGCG is also synthesized chemically, by the transformation of retero-chalcones into 
1, 3-diarylpropene which are then subjected to asymmetric dihydroxylation. The resulting 
diarylpropane-1, 2-diols serve as Chiron’s for essentially enantiopure flavan-3-ols. 28-30 
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1.2.4 Bioactivity 
     Various diseases like cardiovascular diseases and cancer are considered to be caused 
by the activity of oxygen radicals; hence they are expected to be prevented by  
antioxidative compounds. It is well recognized that tea catechins (+) catechin (+C), (-)- 
epicatechin (-EC), (-) epigallocatechin (-EGC), (-) – epigallocatechin (-EGC), (-) - 
Epigallocatechin gallate show potent antioxidant activity. 73, 74 Epidemiological studies 
have shown that the intake of tea catechins decrease the risk of coronary heart disease, 
stroke and cancer. 75-77 Hence analysis of radical scavenging activity of the phenolic 
compounds present in different types of teas (green tea, oolong tea, black tea) has gained 
in importance.  Different techniques such as the oxygen electrode method, 69 High 
performance liquid chromatography, 70 Electron spin resonance spectrometry, 71 Nuclear 
magnetic resonance 72 etc are used to analyze the scavenging activity of catechins on free 
radicals.  
     As mentioned earlier, epigallocatechin gallate (EGCG), the most abundant catechin in 
tea catechins, is shown to have the most effective scavenging activity among the tea 
catechins. 67 The ortho trihydroxy group in the B ring and the galloyl moiety attached at 
3rd position contribute to the strong scavenging activity of Epigallocatechin gallate. 68 
                            
 
 
Figure 1.11: Structure of Catechins (68) 
 
   To elucidate the molecular mechanism underlying the radical scavenging and 
antioxidant activities of antioxidants, (+)-catechin was reacted with 1, 1- diphenyl-2-
picrylhydrazyl (DPPH; stable free radical) as a model reaction.  The reaction mixture is 
analyzed by C13 NMR.  Two new carbonyl peaks were detected in the spectra, and the 
disappearance of characteristic peaks of the B ring was also observed, suggesting that two 
hydroxyl groups in the B- ring are more important in radical scavenging activity among 
the 4 phenolic hydroxyl groups of catechin and the B ring was changed to a quinone 
structure. Signals ascribable to A and C ring remained unchanged. 72
                                 
 11
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A C
B
 
Figure 1.12: Structure of Catechin 
 
     Experimental results have shown that the galloyl moiety in epigallocatechin gallate is 
more important in radical scavenging activity than the hydroxyl groups on the B ring. 72
                                              
                                                 
 
Figure 1.13: Galloyl Group 
 
      Therefore catechins are useful in the prevention of diseases caused by oxygen 
radicals. Consumption of green tea can decrease the cholesterol absorption, can decrease 
the body weight by interfering with sympathoadrenal system, inhibit the low density lipid  
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oxidation (LDL), antithrombotic activities and decrease the systolic and diastolic blood 
pressure. 79 Catechins may ameliorate the impairments or injuries caused by intracellular 
active oxygen (Senile disorders), and might become useful for protecting human from 
Alzheimer’s disease. 78 
     EGCG, the most abundant catechin of green tea catechins, has several health benefits. 
However the beneficial effects of EGCG on human diseases are inconclusive, therefore 
epidemiological studies on protective action of green tea and EGCG yet to be explored 
 
1.3 Crystal engineering 
1.3.1 Introduction 
     Crystal engineering “the design of solids” 62 is target oriented and property directed 
synthesis of molecular crystals. 80 Traditionally, crystal engineering focuses on the 
relationship between the structure and properties of solids. Currently this concept is  
expanded into diverse areas such as material chemistry, supramolecular chemistry, 
molecular recognition and biology. 81
     The term “Crystal engineering” was introduced by Pepinsky (1955) in the context of 
crystallization of organic ions with metal complexes. 63 Schmidt applied the concept of 
crystal engineering in the context of solid state photodimerisation reactions. 64 Modern 
Crystal engineering can be described as an interdisciplinary subject, owing to its 
implications for organic, inorganic, metal organic, theoretical and materials chemistry. 65 
A more useful definition for crystal engineering is provided by Desiraju, who illustrates  
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crystal engineering as a field with broader discipline “designing crystals with desired 
properties”. 
  Definition 
“Crystal engineering is the understanding of intermolecular interactions in the context of 
crystal packing and in the utilization of such understanding in the design of new solids 
with desired physical and chemical properties”. 62
                                                                                           Gautam Desiraju. 
     The concept of crystal engineering has been successfully exploited in the synthesis of 
porous solids 82 and ion exchange materials. 83 Crystal engineering strategies are applied 
in the design of pharmaceuticals, 38 photographic materials, 84 and in novel optical, 
electronic and magnetic materials.                          
1.3.2 Pharmaceutical Crystal Forms 
       The majority of the drug substances are solid dosage forms, most of which contain 
active ingredient in a crystalline state. The inherent stability of crystalline materials and 
the well established impact of crystallization process on purification and isolation have 
made the chemists and the engineers to deliver the pharmaceutically active compounds in 
crystalline form. 31 The physical properties of the crystal such as purity, size and shape 
are determined by the operating conditions of crystallization process, in turn these 
properties determine the efficiency of the operations filtration, drying, formulating and 
also product effectiveness such as bioavailability and shelf-life. Drug dissolution and 
toxicity are affected by solid state phase and purity of the product, this leads to batch to  
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batch uniformity and consistency. Therefore, improved control of crystallization 
processes can achieve better crystal product quality, shorter process time and elimination 
of compromised batches. 32 
       Pharmaceutical crystals may be chiral or achiral and they may exist in different 
forms, salts, solvate or hydrate and polymorphs. The existence of a crystal in different 
crystalline phases results in polymorphs. 40 Solvates are “Molecular complexes that have 
incorporated the crystallizing solvent molecule in their crystal lattice”. 41 When a crystal 
lattice incorporates water, it is designated as a hydrate. Approximately one third of 
pharmaceutical substances are capable of forming crystalline hydrates. 42 Solvates and 
hydrates demonstrate different solubilities and dissolution rates when compared to their 
unsolvated counter parts. 43 The stability of the hydrates and solvates at different 
temperatures and different vapor pressure, differ from their unsolvated forms. 44 These 
differences can influence the stability of the pharmaceutical substances under different 
storage conditions. 
 The physical and chemical properties of a crystal depend upon the arrangement of the 
molecules in it and the physiochemical properties of the solid drug can affect its 
performance. Thus a study of the crystalline state can lead to an understanding of the 
drug properties which are important for preformulation and formulation. Different crystal 
packing changes the periodicity of the molecules which may in turn change physical 
properties of various crystal forms. 40, 45 Therefore, different solid forms can show 
different physical and chemical properties. Pharmaceutical drugs with different solid  
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forms can lead to phase transformations during processing and formulation, such as in 
theophylline, 46 carbamazepine, 47 Phenobarbital, 48 lactose 49 etc.  The stability and 
bioavailability of the drug are affected by these phase changes. 50 Therefore, an 
understanding in relationship between the solid state properties and crystal structures can 
be utilized for optimizing formulation strategies and in designing suitable stability 
protocols. 51, 52 Different solid forms of excipients, used in pharmaceutical formulations, 
can also affect the final physical form of a tablet. 53, 54
     Opposite enantiomers of chiral drugs, show different pharmacological, toxilogical, 
pharmacodynamic and pharmacokinetic properties. This is due to the molecular 
environment, in which these solids exist. 55, 56 The presence of ions in pharmaceutical 
salts influences the physiochemical properties of the crystals, like dissolution rate, 
stability, solubility and hygroscopicity. 57 
       The structure of the crystal also affects mechanical properties, for example the 
intermolecular hydrogen bonds in theophylline monohydrate results in higher mechanical  
strength and less brittle than the anhydrous form of theophylline. 58 Similarly, the 
presence of water molecules in the monohydrate of 4-hydroxy benzoic acid facilitates its 
plastic deformation. 59 Therefore, it is possible to predict the mechanical properties from 
its crystal structure. 
     Different crystal forms of drug substances with different physiochemical properties 
can also affect scale up and transfer from laboratory quantities and procedure through 
pilot plant and full production. 60 The characterization of crystal forms plays a major role 
in quality control and regulatory processes. 61
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Physiochemical properties including mechanical properties of crystalline drug are 
determined by its molecular arrangement, packing, conformation and intramolecular 
interactions in its lattice. These physiochemical properties affect the pharmaceutical 
properties of the drug product. In order to predict the properties of pharmaceutical 
crystals a thorough understanding of the underlying crystal structure is desirable. 40  
1.3.3 Patent Relevance of Crystal Forms 
      “Patents are a mechanism for promoting research for society’s benefit: the right to 
exclude others from practicing a patented invention affords an economic incentive to the 
inventor, while the limited term of the exclusionary right ultimately delivers the invention 
into the public domain”. 87
                                                                               Andrew V. Trask 
     Patent can be defined as “A license conferring the sole right to manufacture, sell, or 
deal in a product or commodity; (now) spec. a license from a government conferring for a  
set period the sole right to make, use, or sell some process or invention”.      
                                                                                          Oxford English Dictionary 
 
Criteria for obtaining a patent: 
 
     A product or process must have novelty (not part of the “state of the art”), utility (must 
serve some worthwhile practical use), and must not be obvious (competent but without 
imagination). A product must be of human ingenuity, and should contain an enabling 
description.  
                                                                                                M.J. Zaworotko 
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    Newness of the drug product can be attributed not only for a new bioactive chemical 
form, but also for a different solid state form (polymorphic, amorphous or chiral), 
combination with other solids (carriers, coating, excipients), and different delivery 
method or even for a different proportion of the drug in this combination 85 are patented.  
     Crystallization methods for a particular solid state form, new drugs, related 
manufacturing, and formulation aspects are protected by patents.  
Examples  
• Co-crystallization process (patent number; WO0053283, Authors; Reuter Karl, 
Reuter Chemische Apparatebau) 
• A process for preparation of urea complexes of vitamin E and its esters (Patent 
number; IN182620, Authors; Bajaj Vikas; Madan Anil Kumar ) 
• High-throughput formation, identification, and analysis of diverse solid-forms 
(patent number; 20030162226, Authors; Cima, Michael J.; Levinson, Douglas; 
Lemmo, Anthony V.; Galakatos, Nicholas; Putnam, David A.;) 
• Novel Conazole crystalline forms and related processes, pharmaceutical  
compositions and methods (patent number; WO03101392, Remenar Julius; 
MacPhee Michael; Peterson Matthew Lynn; Morissette Sherry L; Almarsson 
Orn)  
  Crystal forms of the chemical substances are patented on their powder X-ray diffraction 
pattern, because the powder pattern of a crystalline form is recognized as a finger print of 
it. Chemical substances can exist in more than one crystal form; this phenomenon is 
referred to as polymorphism. As different polymorphs of the same drug can exhibit  
 
widely different solubility and bioavailability properties, polymorphism became an 
immediate concern for pharmaceutical industries during patent filing. A polymorph of a 
drug can be entitled to a different patent protection, as it has a different legal entity. For 
example, the two polymorphs of Zantac (ranitidine hydrochloride) are patented by Glaxo-
Wellcome. 
Ranitidine hydrochloride 86
                       
 
              Figure 1.14: Form I                                Figure 1.15: Form II 
 
Powder pattern for polymorphs of ranitidine 
  
 
 
                                          Figure 1.16: Powder X-ray diffraction of form I and II 
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As methods in generating the new patents guarantee the future financial security of the 
company, a complete screening and characterization of single crystal forms and 
development of corresponding crystallization techniques should be carried out as early as 
possible. 
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2. CSD STATISTICS 
2.1 Cambridge Structural Database (CSD) 
      
     Cambridge Crystallographic Data Centre (CCDC) was established by Olga Kennard at 
Cambridge University in 1965. Cambridge structural data base is the principal product of 
the CCDC. 33 The CSD comprises software for database access, structure visualization, 
data analysis, and structural knowledge bases derived from the scientist’s world wide. It 
records X-ray and neutron diffraction data of organic and metal organic compounds. It 
also records bibliographic, chemical and crystallographic information of these 
compounds. Crystallographic information includes single crystal studies and powder 
diffraction studies. Crystal structure data arising from the publications in the open 
literature and from private communications are also included in CSD. 
CSD software includes ConQuest (search program), Mercury (visualiser), Vista 
(statistical analysis), and Prequest (database creation) (33).  
2.2 Supramolecular chemistry  
     “Supramolecular chemistry” 90which is also known as “chemistry beyond the 
molecule” 91is based on the selective recognition of molecules which interact via non 
covalent forces to form well organized assemblies. During the 1960’s and 1970’s much 
of the supramolecular chemistry research, involved in host guest systems 91 for selective  
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binding of small alkali metal cations by macrocyclic receptors. The fascination for 
molecular recognition phenomenon inspired chemists in further exploration of 
supramolecular systems in the context of weak intermolecular interactions such as 
hydrogen bonds. 92-98 
2.3 Supramolecular synthons 
              
       The term synthon was introduced by Corey in 1967 (99).  Corey defined synthon as; 
“ ……. Structural units within the molecules can be formed or assembled by known or 
conceivable synthetic operations”. The term synthon is traditionally used in representing 
the key structural features in target molecule in organic synthesis. 
      Crystal engineering has emerged around the idea of establishing and later utilizing the 
intermolecular interactions to govern the crystal packing with reasonable predictability. 
In this respect the term supramolecular synthon was introduced by Desiraju in 1995. 34 It 
is defined as “a structural unit within the supermolecule which can be formed and/or 
assembled by known or conceivable intermolecular interactions”. Supramolecular 
synthons are also called as motifs 100 or patterns. 101 They can also be regarded as regions 
within a crystal structure where the recognition between constituent functional groups 
occurs. 102 Supramolecular synthons can be separated in to two distinct categories: 
Supramolecular homosynthon; which results from interaction of identical self-
complementary functionalities 35 and supramolecular heterosynthon which results from 
interaction of different but complementary functionalities35. Examples of supramolecular  
homosynthons include carboxylic acid and amide dimmers, 103,104 while supramolecular  
 
heterosynthon include acid-pyridine, 35acid –amide 105-108and hydroxyl- pyridine.109-111 
Figure 2.1 represents the acid-acid dimmer (homosynthon) and acid – pyridine 
(heterosynthon). 
                                                                                                  
                
 
     Figure 2.1 Examples of supramolecular homosynthon (left) and supramolecular heterosynthon 
(right) 
     Supramolecular homosynthons tend to be observed in single component crystals, but 
their existence can also be observed in multiple component crystals in which each 
component has at least one identical functional group. Furthermore when multiple 
functional groups are present the formation of a supramolecular heterosynthon is 
possible. Supramolecular heterosynthon can exist between the functional groups located 
on two different molecules with same chemical make up or on the two different 
molecules with different chemical make up. Interpretation of existing crystal structures 
with complete knowledge on interplay between supramolecular synthons would help in 
designing new multicomponent crystals. 
2.4 CSD Statistics for Polyphenols 
The polyphenolic nature of the flavonoids provoked an interest to conduct a survey on 
intermolecular interactions of phenols and polyphenols in the CSD. Phenols and  
polyphenols are evaluated by considering the following constraints, no ions, only  
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organics, R factor: <=0.075, structures containing 3D coordinates. As EGCG contains 
ether, ester and alcohol groups, while the two known solvates of it contain acetonitrile 
and nitrobenzene, studies are conducted considering these functional groups. 
There are 6,032 phenols in CSD as of May 2007. Out of 6,032 phenols 1,005 are 
polyphenols. 
                                      
                                          
OH 
OH 
 
                              Figure 2.2: Structure of polyphenol considered in the CSD search 
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Figure 2.3: Synthon I; OH---OH, Synthon II  OH---CO,  Synthon IIIOH----O(ether) interactions,            
(R:C6H5OH)  
   
     
 
 24
 In CSD analysis, the frequency of occurrence of supramolecular synthons hydroxyl to 
hydroxyl (synthon I), hydroxyl to carbonyl of ester (synthon II) and hydroxyl to ether 
(synthon III) in phenols and polyphenols is evaluated.  In order to determine appropriate 
distance ranges, within which homo and heterosynthons exist, distance histograms were 
generated. Based on visual inspection of the resulting interactions in the crystal structures 
included in the histograms, the lower and higher cut offs for hydrogen bond distances 
were determined.  The histograms (Fig 0.2) revealed that hydroxyl to hydroxyl synthon 
(I) occurs within a distance range of 2.6-3.0 Å. Supramolecular synthons II (hydroxyl to 
carbonyl of an ester) and III (hydroxyl to ether) exist within a range of 2.56-2.94 Å and 
2.5-3.0 Å respectively.   
 
                 
 
                             
Figure 2.4:Histograms of contacts for supramolecular synthons I (OH---OH), II (OH---CO) and 
(OH----O) III 
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Figure 2.5: Synthon IV represents OH---CN and Synthon V represents OH---NO interaction 
 
     Similarly hydroxyl to cyano group Synthon (synthon IV as represented in figure 2.5) 
and hydroxyl to nitro group synthon (synthon V as represented in figure 2.5) were 
evaluated. Histograms revealed the distance ranges within which these synthons occur are 
2.7- 3.2 Å and 2.78 - 3.06 Å respectively.  
 
        
 
 
            Figure 2.6 : Histograms of contacts for supramolecular synthons IV  
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Phenols 
 
Polyphenols 
 
 
 
Synthon I 
 
(OH---OH) 
 
836 hits/6,032  
14.8% 
 
 
385 hits/1,005 
38.3% 
     
Table 2.1: Frequency of occurrence of synthon I in phenols and polyphenols 
 
 
 
Phenol + 
Ester 
 
 
OH--CO 
(ester) 
2.56-
2.94Å 
 
Phenol+ 
ether 
 
OH---O 
(ether) 
2.5-3.0 Å 
 
 
Phenol    
+ Cyano 
group 
 
OH---CN 
2.7 -3.2Å 
 
Phenol + 
Nitro  
group 
 
OH---NO 
2.78-
3.06Å 
 
 
 
 
 
Phenols 
 
 
 
 
799 
hits/6,032 
phenols 
 
 
 
225 
hits/799 
 
 
 
 
2,074 
hits/6,032 
 
 
 
 
199 hits/ 
2,074 
 
 
 
 
187 hits/ 
6,032 
 
 
 
 
74 hits/ 
187 
 
 
 
 
370 hits/ 
6,032 
 
 
 
 
83 hits/ 
370 
 
 
 
 
 
Polyphenols 
 
 
 
 
 
191 hits/ 
1,005 
polyphenols 
 
 
 
 
 
81 
hits/191 
 
 
 
 
 
 
281 
hits/1,005 
 
 
 
 
 
50 
hits/281 
 
 
 
 
 
38 hits/ 
1,005 
 
 
 
 
 
21 
hits/38 
 
 
 
 
 
31 hits/ 
1,005 
 
 
 
 
 
11 hits/31 
 
 
 
 
Table 2.2: Frequency of occurrence of synthons from II to V in phenols and polyphenols 
 
     Table 2.2 represents the frequency of occurrence for synthons II to V in the presence 
of the respective functional groups with phenols and polyphenols. Though the presence 
of ethers with phenols and polyphenols is high in comparison with other functional  
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groups, the occurrence of synthon III is relatively lower compared to the other synthons. 
 
Supramolecular 
synthons 
 
    D----A (Å) 
 
Mean (Å) 
 
OH----OH  
 
2.6 -3.0 Å 
 
2.80 
 
OH---CO (ester) 
 
2.56-2.94 
 
2.771 
 
OH---O (ether) 
 
    2.5-3.0 
 
2.805 
 
OH----CN (cyano) 
 
2.7-3.2 
 
2.873 
 
Table 2.2.3: Distance ranges within which different synthons exists 
 
 This analysis has revealed that the frequency of occurrence of hydroxyl to hydroxyl 
synthon (synthon I) is higher in phenols (14.8%) and polyphenols (38.3%), when 
compared to other synthons (II, III, IV and V). The prevalence of the specific 
supramolecular synthons in these crystal structures would provide a valuable insight for 
crystal engineering strategies in generation of new multicomponent materials comprised 
of polyphenols. 
 
 
 
 
 
 
 
 
 29
 
 
3. EXPERIMENTAL DATA 
 
     Some solvents were obtained from Sigma Aldrich. Distillation of few solvents was 
performed in the lab itself, such as methanol, ethanol, dichloromethane, chloroform. 
Distilled water is used. EGCG was provided by Dr. Roland Shytle.   
3.1 Infrared Spectroscopy (IR) 
 
     A Nicolet Avtar 320 Fourier transform Infrared spectrometer was used for collecting 
the IR spectra of the samples (sample concentration 2mg). The spectra were measured 
over the range of 4000 – 400cm-1. Data were analyzed by using EZ Omnic software. 
3.2 Differential Scanning Calorimetry (DSC) 
     Thermal analysis of the samples was performed on TA instrument DSC 2920 
equipped with liquid nitrogen cooling. The samples of crystals (2mg-7mg) were placed in 
aluminum pans, and were scanned at 10° C/min in the range 25° - 350° C under a dry 
nitrogen atmosphere (flow rate 70ml/min). The data were managed by TA universal 
analysis. 
3.3 Powder X-ray Diffraction (PXRD) 
     PXRD patterns were collected on Bruker AXS D 8 powder diffractometer with a Cu 
Kα radiation (1.540 56Å). The tube voltage and amperage were set at 50kV and 40mA, 
respectively. Each sample was scanned between 3 and 40° in 2θ with a step size of 0.02°.  
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The experimental PXRD patterns and calculated PXRD patterns from single crystal 
structures were compared to confirm the composition of materials. 
3.4 Single Crystal X-Ray Crystallography 
     Crystals of forms II, III and IV were examined under a microscope and suitable single 
crystals were selected for X-ray analysis. Data were collected on a Bruker–AXS SMART 
APEX CCD diffractometer with monochromatized Mo Kα radiation (λ = 0.71073 Å) 
connected to KRYO-FLEX low temperature device. Data were collected at 100 K. 
 Lattice parameters were determined from least square analysis, and reflection data were 
integrated using the program SAINT. Lorentz and polarization corrections were applied 
for diffracted reflections. In addition, the data was corrected for absorption using 
SADABS. Structures were solved by direct methods and refined by full matrix least 
squares based on F2 using SHELXTL. All non-hydrogen atoms were refined with 
anisotropic displacement parameters. All H-atoms bonded to carbon atoms, except 
methyl groups, were placed geometrically and refined with an isotropic displacement 
parameter fixed at 1.2 times Uq of the atoms to which they were attached. N or O bonded 
protons, as well as H-atoms of methyl groups, were located from Fourier difference map 
and refined isotropically based upon the corresponding N, O or C atom (U(H)=1.5Uq(N, 
O)).  
 
 
 
 
3.5 Form I 
     90% pure EGCG provided by Dr.Roland Douglas Shytle is considered as form I. Up 
to the date the reported form of egcg in literature is form I. This is confirmed by  
PXRD. 88  
3.5.1. Physical properties 
     Melt-Temp: 220° C, Soluble in ethanol, methanol, ethyl acetate, acetonitrile, acetic 
acid, formic acid. It is insoluble in chloroform, cyclohexane, toluene, and hexane. Egcg is 
sensitive to light, so it is stored at temp 2°- 8°C.  
3.5.2 IR of Form I 
     The IR of form I match with the IR found in literature. 89
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                                                          Figure 3.1: IR of Form I 
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3.5.3 DSC of Form I 
 
     Phase transitions are observed at 126.43° C and 227.71°C. DSC matches with the 
DSC in the literature. 88              
 
                                                                Figure 3.2: DSC of Form I 
 
 
                                                     Figure 3.3: DSC of Form I from Literature 
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3.5.4 Powder X-ray Diffraction of EGCG form I 
 
     PXRD of 90% pure EGCG matches with PXRD of EGCG obtained in the literature. 
Major peaks; 90% egcg (literature) 5.32 (5.72), 8.63 (8.63), 10.48 (10.4), 12.24 (11.998), 
17.14 (16.993), 20.86 (20.656), 24.541 (24.66), 29.68 (29.653). 
              
                                      Figure 3.4: PXRD of Form I       
 
 
                                                     Figure 3.5: PXRD of Form I from literature 
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3.6 Form II 
 
3.6.1 Synthesis  
     65mg of 90% pure epigallocatechin gallate (0.141 moles) dissolved in 1ml of 
acetonitrile (99% pure) is layered on 2.5 ml of dichloromethane and allowed to stand in 
refrigerator. After 72 hours colorless platelet crystals (Form II) were observed. An 
increase of 3-fold and 5-fold in contents has shown same results.  Form II was also 
crystallized from acetonitrile and chloroform.  
3.6.2 Physical properties 
 
     Melt- Temp: 235-238°C. Solubility properties are observed to be similar to that of 
Form I. Crystals are stable up to four days at temperature 2° to 8° C. Upon heating at 
120° C for twenty minutes, solvent is evaporated, and Form II is converted to Form IV.  
3.6.3 IR of Form II 
 
     IR of form II shows O-H stretch 3323.8 cm-1, C=O stretch at 1605 cm-1, and 
aromatic carbon stretch at 742.4 cm-1. 
       
74
2.
49
82
4.
22
98
7.
29
10
33
.8
3
10
97
.2
2
11
40
.1
1
12
08
.0
3
12
42
.1
21
31
5.
48
13
81
.0
8
14
49
.9
4
15
14
.4
3
15
35
.3
8
16
05
.0
1
33
23
.8
1
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
%
T
 1000   2000   3000   4000  
Wavenumbers (cm-1)   
                                                            Figure 3.6: IR of Form II 
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 3.6.4 DSC of Form II  
     Phase transitions are observed at 101.43° C and 252.71°C. 
          
                              
                                                       Figure 3.7: DSC of Form II 
3.6.5 TGA of Form II 
     Below 100° C 16.68 % weight loss is observed. 20.20 % weight loss is observed 
between 230° C. 
                
                                            Figure 3.8: TGA of Form II 
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3.6.6 Powder X-ray Diffraction of form II  
     The experimental PXRD matches with the calculated PXRD as shown in fig 3.11. 
Major peaks, experimental (calculated):  7.12 (7.12), 7.8 (7.92), 8.46 (8.56), 13.04 (13.3), 
15.24 (15.28), 23.54 (23.86), 25.92 (25.44). 
 
 
                                                          Figure 3.9: Experimental PXRD of Form II 
 
 
 
                                                          Figure 3.10: Calculated PXD of Form II 
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                                Figure 3.11: Calculated Vs Experimental PXRD of Form II 
 
3.6.7 Picture of Single crystal 
 
                
   
                             Figure 3.12: Single crystal of Form II 
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3.6.8. Single Crystal X-ray Crystallography Data 
      Molecular formula: C24 H21 N O11; Formula weight: 499.42; Crystal system:  
Monoclinic; Space group: C2; Unit cell dimensions: a = 22.876(3) Å, b = 14.9054(17) Å; 
c = 15.8886(18) Å, α =90◦; β =102.688(2)◦;γ = 90°; Volume: 5285.4(10)Å3; Z=8; 
Temperature:100(2) K; Density (calculated): 1.433 Mg/m3 ; λ(Mo-Kα): 0.71073 Å ; 
Reflections measured: 12985; Independent reflections: 10165 [R(int) = 0.0277]; Final R 
indices [I>2sigma(I)]: R1 = 0.0831, wR2 = 0.1993; R indices (all data): R1 = 0.1013, 
wR2 = 0.2144 
 
3.7 Form III 
3.7.1 Synthesis 
     In a typical reaction, a reaction tube with 6ml of dichloromethane is taken, and 1ml of 
nitrobenzene is layered on it. 200mgs (0.436mmoles) of 90% pure EGCG dissolved in 
2.5ml of acetonitrile is layered on nitrobenzene. Reaction test tube is left on refrigerator, 
after 24 hours yellow needle like crystals were observed 
3.7.2 Physical properties 
     Melt Temp: 235 °-238°;  Solubility properties are similar to that of Form I. Form III 
crystal are more stable compared to Form II crystals at temp 2°- 8° C. Upon heating to 
120° C for twenty five minutes, Form III converts to Form IV. 
 
 
 
 
 
3.7.3 IR of Form III 
     3272.3 cm-1 (O-H stretch), 1681.33 (N-O stretch) are observed. 
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                                                     Figure 3.13: IR of form III 
 
3.7.4 DSC of Form III 
     Phase transitions are observed at 140.10°C, 169.26° C, and 253.52°C.             
 
 
                                                                Figure 3.14: DSC of Form III 
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3.7.5 TGA of Form III 
     11.98 % of weight loss is observed at 131° C, 25.31 % of weight loss is observed at 
211.36° C is observed. 
  
                                                    Figure 3.15: TGA of Form III 
 
3.7.6 Powder X-ray Diffraction of form III 
     The experimental PXRD matches with the calculated PXRD as shown in fig 
3.18.Major peaks, Experimental (calculated): 13.4 (13.4), 15.4 (15.4), 19.4 (19.44), 24.3 
(24.4), 27.8 (27.65), 28.5 (28.5), 31.3 (31.3), and 37.6 (37.5) 
 
                                                                  Figure 3.16:  Experimental PXRD of Form III 
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                                             Figure 3.17: Calculated PXRD of Form III 
 
 
 
                                   Figure 3.18: Calculated Vs Experimental PXRD of Form III 
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3.7.7. Picture of single crystal 
    
 
                        Figure 3.19: Single crystal of Form III 
 
3.7.8. Single Crystal X-ray Crystallography Data 
     Molecular formula: C28 H25 N O14; Formula weight: 599.49; Crystal system: 
Orthorhombic; Space group: P2(1)2(1)2(1); Unit cell dimensions: a = 13.2070(14) Å, b = 
13.2134(14) Å; c = 14.5781(16) Å, α = β = γ = 90°; Volume: 2544.0(5) Å3; 
Z=4;Temperature:100(2) K; Density (calculated): 1.565 Mg/m3 ; λ(Mo-Kα): 0.71073 Å ; 
Reflections measured: 11442; Independent reflections: 4964 [R(int) = 0.0608]; Final R 
indices [I>2sigma(I)]: R1 = 0.0605, wR2 = 0.1126; R indices (all data): R1 = 0.0787, 
wR2 = 0.120 
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3.8. Form IV 
3.8.1 Synthesis 
     Form IV is obtained by heating form II and III at 120° for 20-25 minutes. Form IV 
crystals: EGCG (45mg, .098mmoles of form IV powder obtained by heating form III at 
120◦ C for 25 minutes) is dissolved in 1ml of acetonitrile (99%pure, Aldrich). The 
solution is layered on 2.5ml dichloromethane (distilled and stored over molecular sieve) 
and seeded with form IV crystals obtained by heating form III (at 120◦ C for 25 minutes) 
and was allowed to stand  in  refrigerator. After one week colorless needle like crystals 
were observed. 
3.8.2. Physical Properties 
     Melt-Temp: 232°-235°. Solubility properties are similar to that of form I. 
3.8.3. IR of Form IV 
     3466.81cm-1 (O-H stretch), 1606.19 (C=O) stretch are observed. 
 
                 
   
                                                 Figure 3.20: IR of Form IV 
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 3.8.4 DSC form IV  
     Phase transition is observed at 250.08 °C 
 
                                    
                                                                  Figure 3.21: DSC of Form IV 
 
 
3.8.5 TGA form IV                    
 30.02 % of weight loss is observed at 251.78° C. 
                       
                                       Figure 2.22: TGA of  Form IV 
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3.8.6 Powder X-ray Diffraction of form IV  
 
     The experimental PXRD matches with the calculated PXRD as shown in fig 3.24. 
Major peaks (experimental): 13.9 (13.84), 17.2 (17.12), 21.2 (21.16), 23.6 (23.64), 26.5 
(26.6), 29.0 (29.16), and 31.5 (31.7). 
                                       
 
                                       Figure 3.22: Experimental PXRD of Form IV 
 
                                 Figure 3.23: Calculated PXRD of Form IV 
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                                            Figure 3.24: Calculated Vs experimental PXRD of Form IV 
 
3.8.7 Picture of Single Crystal 
 
 
 
Figure 3.25: Single crystal of Form IV 
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3.8.8 Single Crystal X-ray Crystallography Data   
     Molecular formula: C22H18O11; Formula weight:458.36; Crystal system: Monoclinic; 
Space group: P2(1); Unit cell dimensions: a = 13.006(10) Å, b = 5.686(4)Å; c = 
13.089(10) Å, α = 90°;β =107.062(11)° ;γ = 90°; Volume: 925.4(12)Å3; Z=2; 
Temperature: 100(2) K; Density (calculated): 1.645 Mg/m3 ; λ(Mo-Kα): 0.71073 Å ; 
Reflections measured: 2623; Independent reflections: 2550 [R(int) = 0.0312]; Final R 
indices [I>2sigma(I)]: R1= 0.0641, wR2 == 0.1494; R indices (all data): R1 =0.0800, 
wR2 = 0.1674 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. RESULTS AND DISCUSSION 
 
4.1 Structure Description 
     EGCG structure; EGCG consists of 4 rings (A, B, C, D) with 8 hydroxyl groups, as 
shown in Fig4.1. In all forms of EGCG the A and C ring lie in one plane while rings B 
and D lie in different planes with different dihedral angles. EGCG makes full use of all 
hydroxyl groups to form different synthons such as hydroxyl to hydroxyl, hydroxyl to 
ether, hydroxyl to carbonyl of ester, hydroxyl to cyano and hydroxyl to nitro. 
                                  
A C
B
D
Figure 4.1: Structure of EGCG 
 
4.1.1 Form II 
     The crystal structure of form II was obtained from Single crystal X-ray diffraction as  
described in the experimental section. Form II solvate of acetonitrile, crystallizes in the  
 48
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onoclinic C2 space group with two egcg and two acetonitrile molecules and some 
 
to 
n between, the two hydroxyl groups of the D 
 two 
.  
 
     
m
disordered solvent molecules in asymmetric unit. Analysis of the structure of form II
indicates the presence of four type’s synthons. They are hydroxyl to hydroxyl (OH---
OH), hydroxyl to ether (OH---O), hydroxyl to cyano group (OH---CN), and hydroxyl 
carbonyl of ester (OH---CO) synthons.  
     The OH---OH hydrogen bond exists i
ring of molecule I and one hydroxyl group of B ring of molecule II. The OH---OH 
hydrogen bond is observed between hydroxyl group on the B ring of molecule I and
hydroxyl groups of D ring of molecule II and also in between the hydroxyl group on the 
A ring of molecule I and the hydroxyl group of A ring on molecule III. The hydrogen 
bond distances in synthon OH----OH are 2.999Å, 2.733Å, 2.753Å, 2.838Å, and2.603Å
The distances are consistent with the CSD analysis (2.6 – 3.0Å).  
 
 
Figure 4.2:  Representation of OH----OH synthon in Form II 
Molecule  
    II 
Molecule  
     I Molecule  
    III 
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he OH---O (ether) hydrogen bond exists between the oxygen of the C ring and the 
hydroxyl of the D ring. The hydrogen bond distance in OH---O synthon is 3.026Å which 
is consistent with the CSD analysis (2.5-3.0Å). 
                   
 in form II 
     The OH---CO (ester) hydrogen bo olecule I 
and the hydroxyl on the D ring of molecule II and also with the two hydroxyl groups on 
the B ring of molecule II. The hydrogen bond distances in synthon OH---CO are 2.847Å, 
2.924Å, and 2.680Å. The distances are consistent with the CSD analysis (2.56-2.94Å). 
 T
 
Figure 4.3: Representation of OH---O synthon
nd exists between the ester carbonyl of m
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Molecule  
     I 
Molecule 
   II 
Molecule III 
Figure 4.4: Representation of OH---CO synthon in form II 
                          
     The OH---CN hydrogen bond exists between the hydroxyl group on the B ring and 
cyano group of acetonitrile molecule. The hydrogen bond distance in the synthon OH---
CN is 2.898Å which is consistent with the CSD analysis (2.7-3.2 Å). 
                                          
Figure 4.5: Representation of OH---CN synthon in form II 
     
 Acetonitrile molecules are embedded in between egcg molecules and sustained by 
hydrogen bonding. 
      
Figure 4.6: Solvent entrapment in form II 
  
     Unit cell packing of form II includes 8 egcg molecules, 8 acetonitrile molecules, and 
disordered solvent molecules. 
                      
                            Figure 4.7: Unit cell packing of form II 
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4.1.2 Form III 
     Form III solvate of nitrobenzene crystallizes in orthorhombic P2 (1) space group with 
one egcg molecule, one nitrobenzene and one water molecule in asymmetric unit. 
Analysis of form III crystal indicated the presence of four types of synthons. They are 
hydroxyl to hydroxyl (OH---OH), hydroxyl to carbonyl of ester (OH---CO), hydroxyl to 
nitro (OH---NO) and hydroxyl to oxygen in water (OH---O).   
     Figure 4.7 represents the OH----OH interactions of molecule I and molecules II, III, 
IV and V. One of the hydroxyl group on the A ring of molecule I and hydroxyl groups on 
the B and D ring of molecule V form hydrogen bond. The other hydroxyl group of A ring 
in molecule I forms hydrogen bond with the hydroxyl group on the B ring of molecule II. 
The hydroxyl group on the B ring (of molecule I) forms hydrogen bond with hydroxyl 
group on the B ring of molecule III. The two hydroxyl groups on D ring (molecule I) 
form hydrogen bond with hydroxyl group on the A ring of molecule IV and also with 
hydroxyl group on the B ring. The hydrogen bond distances in the synthon OH----OH are 
2.910Å, 2.827Å, 2.831Å, 2.827Å, 2.910Å, and 2.982Å. The distances are consistent with 
the CSD analysis (2.6-3.0Å). 
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Molecule I 
Molecule II 
Molecule III 
Molecule  IV 
Molecule V 
Figure 4.8: Representation of OH----OH synthon in Form III 
      
The OH---CO (ester) hydrogen bond exists between the carbonyl of the EGCG molecule 
and the hydroxyl group on the A ring of another EGCG molecule. The hydrogen bond 
distances in OH—CO synthon is 2.671Å which is consistent with the CSD analysis 
(2.56-2.94Å). 
                                   
Figure 4.9:  Representation of OH---CO synthon in Form III 
      The OH---NO hydrogen bond is observed between the hydroxyl group of B ring and 
nitro group of nitrobenzene. Hydrogen bond distance in the synthon OH---NO is 2.773Å 
which is consistent with the CSD analysis (2.7- 3.2Å).  
                    
Figure 4.10: Representation of Synthon OH---NO in Form III 
 
     The OH—O hydrogen bond is observed between the hydroxyl groups on B ring and 
oxygen of water molecule. The hydrogen bond distances in the synthon OH---O (water) are 
2.837Å, 2.957Å, and 2.610Å. 
 
                 
Figure 4.11: Representation of Synthon OH---O in Form III 
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 Nitrobenzene molecule is sandwiched between two egcg molecules and sustained by 
hydrogen bond. 
                                  
 
Figure 4.12: Solvent entrapment in form III 
                       
     Unit cell of form III contain 4 egcg molecules, 4 nitrobenzene molecules and 4 water 
molecules 
                         
                
                               
    
                              
                                  Figure 4.13: Unit cell packing of Form III 
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4.1.3 Form IV 
     Form IV of egcg crystallizes in monoclinic P2 (1) space group with one egcg 
molecule in asymmetric unit. Form IV exhibits three types of synthons. They are OH---
OH, OH---CO (ester), and OH----O (ether).                               
 
Figure 4.14:  Representation of Form IV structure 
 
     The OH---OH hydrogen bond in form IV exists between the hydroxyl groups on A 
ring of molecule I and hydroxyl group on B and D rings of molecules VI, and IV 
respectively. The hydroxyl groups on the D ring of molecule I exhibits OH---OH 
hydrogen bond with hydroxyl group on the A and B rings of molecules IV and III 
respectively. The hydroxyl group on the B ring of molecule I exhibits the OH---OH 
hydrogen bond with hydroxyl group on the A ring of molecule II.  The hydrogen bond 
distances in the synthon OH---OH are 2.801 Å, 2.697Å, 2.696Å, and 2.960Å. The 
distances are consistent with the CSD analysis (2.6 -3.0 Å).                 
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 Molecule I 
Molecule II 
Molecule III 
Molecule IV 
Molecule V 
Molecule VI 
 
 
Figure 4.15: Representation of OH---OH synthon in Form IV 
 
     The OH—O (ether) hydrogen bond exists between the hydroxyl group of the B ring 
and the oxygen in the C ring of another molecule. The hydrogen bond distance of synthon 
OH---O is 2.875Å which is consistent with the CSD analysis (2.5-3.0Å).  
                                              
 
Figure 4.16: Representation of OH—O synthon in Form IV 
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The OH---CO (ester) interaction is observed between the carbonyl of molecule I and the 
hydroxyl groups on the B and D rings of molecules II and III respectively. The hydrogen 
bond distances in the synthon OH----CO are 2.813Å, 2.839Å, and 2.879Å. The distances 
are consistent with the CSD analysis (2.56-2.94Å). 
 
Molecule I 
Molecule II 
Molecule III
 
        Figure 4.17: Representation of OH—CO synthon in FormIV 
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Unit cell of form IV contain two egcg molecules 
                         
                                       Figure 4.18: Unit cell packing of Form IV 
 
4.2 Conformational analysis 
      Conformational flexibility in the EGCG molecule was previously analyzed by proton 
NMR. 115 It includes the orientation of the linkage between B, D and C ring owing to the 
puckering of C ring. The conformational changes in C ring with respect to the B and D 
rings, gives rise to 4 conformers (A, B, C, and D). 
    
     Conformer A               Conformer B             Conformer C                 Conformer D 
R1= Pseudoequitorial        R1 = Pseudo axial          R1= Pseudoequitorial         R1 = Pseudo axial 
R2 = Pseudo axial            R2= Pseudoequitorial      R2= Pseudoequitorial         R2 = Pseudo axial 
 60
                                     
                                 Figure 4.19: Representation of different conformations of EGCG (116) 
 
      The pseudoequitorial and pseudoaxial positions of the B and D rings with respect to 
the C ring in forms II, III, and IV suggest that they exist as conformer A. The puckering 
of the C ring generates the pseudoequitorial and pseudoaxial positions of rings B and D.  
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                Form III                                    Form IV  
1 and C2) on C ring exists in S, S, for form II and R, R for 
 
C1 
C2 
C1 C2 C1 
 
 
        Form II 
 
      The two chiral centers (C
C2
 
forms III, IV respectively. 
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4.3 Discussion 
     Although flavonoids are abundant and commercially available they are difficult to 
purify and crystallize. In this respect developing new crystal forms of EGCG was 
challenging. Different crystallization techniques were explored in crystallizing EGCG, 
ch as solvent evaporation, vapor diffusion, slow cooling, and solvent layering. Solvents 
hniques were ethanol, methanol, toluene, cyclohexane, hexane, 1, 4-
nd to 
 
 
sults 
 
                                Figure 4.20: LC-MS analysis of 90% pure EGCG 
               
 
su
used in these tec
dioxane, dimethylsulfoxide, dimethylformamide, chloroform, dichloromethane, 
acetonitrile, nitrobenzene, benzene, and water. Solvent layering technique was fou
be the most successful technique in crystallizing EGCG. As mentioned in chapter 3, two
solvates and a new form of EGCG were obtained by solvent layering technique. 
          Liquid chromatography- Mass spectrometry (LC-MS) was used to evaluate the
purity of crystals of the two solvates and the new form of EGCG. The LC-MS re
have revealed the presence of impurities. An impurity with mass/charge ratio 443 
(retention time 13 minutes), was observed in all three forms. 
                                 
                                              Figure 4.21: LC-MS analysis of Form II 
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                   Figure 4.22: LC-MS analysis of Form III 
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                                                  Figure 4.23: LC-MS analysis of of Form IV 
   
is of all four forms of EGCG.LC-MS 
e; EGCG: 7.609 (Mol.wt of EGCG: 458.4), Impurity: 13.039 
Figures 4.20-4.23 represents the LC-MS analys
Data:  Retention tim
minutes. 
  
Retention 
   time  
 
Bulk 
 
Form II Form III 
 
 
Form IV 
   
7.609 459 (M+1) 
481 (M+23) 
459 (M+1) 459 (M+1) 459 (M+1) 
13.039 443(M+1) 443 (M+1) 443 (M+1) 443 (M
481 (M+38) 506 (M+63) 481 (M+38) 
+1) 
523 (M+80) 
506 (M+63) 506 (M+63) 
    
                   Table 4.1 : Representing the components eluted at different retention times 
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  Here in ble 4.1, bul  represents the 90% pure EGCG. LC-MS results have revealed 
forms, EGCG was elut inutes purities after 
es. Identities of impurities were not determined.    
gh cou
analysis of the existing supramolecular synthons in the new crystal forms can provide an 
 g s cule men ents when 
designing c  C hap lete knowledge 
on interplay between the supramolecular —OH, OH---CO, OH---O, OH---
, OH---O) would help to develop a strategy in choosing the co-crystal formers. 
 
 
 
 
 
 
 
 
 
 
 
   ta k
that from all four ed after 7m  and the im
13minut
    Thou crystallization techniques ld not produce 100% pure EGCG, a careful 
educated uess to choo e other mole  with comple tary compon
o-crystals. Considering the SD analysis (c ter 2), a comp
 synthons (OH
CN
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5. CONCLUSION 
    In summary the study presented herein involves the synthesis of different crystal 
rms of EGCG with limited CSD analysis on supramolecular synthons that exist in these 
rystal forms. In crystallizing EGCG the technique known as solvent layering was found 
 be the most successful technique. Two solvates, with acetonitrile and nitrobenzene, 
nd one new form of EGCG is reported. A total of five types of synthons exist in the 
rystal forms of EGCG. Synthons I (OH---OH), and II (OH---CO (ester)) exist in all three 
rms (II, III and IV). The absence of synthon III (OH---O (ether)) in form III suggests 
at the occurrence of an OH---O (water) synthon in the presence of a competing 
cceptor, ether moiety, is relatively high. Synthons IV (OH---CN) and V (OH---NO) 
xists in form II and form III respectively. All the five synthons occur within the distance 
ranges which are consistent with the CSD analysis. 
 
e 
. 
s  
bient  
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c
to
a
c
fo
th
a
e
         Though EGCG shows profound beneficiary effects on health, it suffers from the
problem of poor bioavailability. This study, on structural features of EGCG, could 
potentially provide valuable information for structural modifications, which may change 
the physiochemical properties of EGCG. One of the future aspects of this study could b
the design of co-crystals of EGCG. A brief description for co-crystals is provided here
          A broad definition for co-crystal is given by Dunitz as “Crystals containing two or 
more components together”. 112 In a more specific way others 113,114 defined co-crystal a
“a multiple component crystal formed between compounds that are solid under am
 67
ith 
g materials, due to being new and 
 
s 
herefore compounds like caffeine and theobromine 
 
 
conditions: at least one component is molecular and forms a supramolecular synthon w
the remaining components”. Co-crystals exhibit different physiochemical properties 
(such as bioavailability, solubility) from their startin
distinct solid state structures.  
    To design co-crystals of EGCG co-crystal formers can be chosen based on CSD 
analysis. A small survey which represents the competitiveness between aromatic nitrogen
and the carbonyl of an ester group to form a hydrogen bond with the hydroxyl moiety on 
phenols is conducted in the CSD. Results have revealed that 36 hits were present 
containing hydroxyl, ester, and aromatic nitrogen groups. Out of these 36 hits, 14 hits 
contain the OH---N (arom) synthon, 7 hits contain the OH---CO (ester) synthon, and 4 hits 
contain the OH---OH synthon. All three synthons occur within the distance range of 2.5-
3.0Å (OH----N (arom)), 2.56-2.94 Å (OH---CO (ester)) and 2.6-3.0 Å (OH---OH) 
respectively. The distances are estimated from histograms generated by the CSD. Thi
study has revealed that the occurrence of the OH----N (arom)   synthon is relatively more 
favored than other synthons.   T
(which contain aromatic nitrogen) could potentially act as good co-crystal formers. 
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